Safety and Performance Using Legion™ CR Oxinium and CoCr Femoral Implants Combined With Legion™/Genesis™ II XLPE High Flex Tibial Inserts
← catalyst calendarNCT03687593 · readout in 408 d
Sponsored by Smith & Nephew, Inc. (industry) · SNN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
126actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-08-26 | actual | When the study began enrolling |
| Primary completion | 2027-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-01 | estimated | The whole study's end, after follow-up |
| First posted | 2018-09-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Total Knee Arthroplasty
Intervention
- Device: Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts
Primary outcome
what the primary-completion date above is the date OFImplant survival 10 years postoperatively
measured 10 years post-op
Permalink · SNN's whole pipeline · Catalyst calendar · Every registered study · What changed